U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H26N3O4S.Na
Molecular Weight 451.514
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AZELOPRAZOLE SODIUM

SMILES

[Na+].CC1=C(OCC2COC(C)(C)OC2)C(C)=C(C[S@@+]([O-])C3=NC4=C([N-]3)C=CC=C4)N=C1

InChI

InChIKey=HXDOUUHARCBYLF-VNUFCWELSA-N
InChI=1S/C22H26N3O4S.Na/c1-14-9-23-19(13-30(26)21-24-17-7-5-6-8-18(17)25-21)15(2)20(14)27-10-16-11-28-22(3,4)29-12-16;/h5-9,16H,10-13H2,1-4H3;/q-1;+1/t30-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C22H27N3O4S
Molecular Weight 429.532
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

E-3710 (Z-215) is a new proton pump inhibitor (PPI). E-3710 irreversibly inhibited H(+),K(+)-ATPase activity in pig gastric vesicles with an acidic internal environment. E-3710 is a long-acting inhibitor of gastric acid secretion and a promising novel therapy for acid-related diseases, such as gastroesophageal reflux disease. E-3710 is metabolized through oxidation, reduction and conjugation. Unchanged E-3710 was excreted in urine at trace levels but was not detected in faces. The major isozyme contributing to the oxidation of Z-215, including the formation of Z-215 sulphone, was CYP3A4. It is useful for treating gastroesophageal reflux disease in all CYP2C19 genotypes. E-3710 is in phase II clinical trial for the treatment of erosive esophagitis and gastro-esophageal reflux.

Approval Year

PubMed

PubMed

TitleDatePubMed
Efficacy and Safety Profile of Z-215 (Azeloprazole Sodium), a Proton Pump Inhibitor, Compared with Rabeprazole Sodium in Patients with Reflux Esophagitis: A Phase II, Multicenter, Randomized, Double-Blind, Comparative Study.
2018
Pharmacokinetics and Pharmacodynamics of Azeloprazole Sodium, a Novel Proton Pump Inhibitor, in Healthy Japanese Volunteers.
2018 Apr
Mass balance and metabolism of Z-215, a novel proton pump inhibitor, in healthy volunteers.
2018 Oct

Sample Use Guides

Once a day within about 30 minutes after breakfast 10, 20, or 40 mg for 8 weeks
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 02:07:41 GMT 2023
Edited
by admin
on Sat Dec 16 02:07:41 GMT 2023
Record UNII
KDJ60607ON
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AZELOPRAZOLE SODIUM
Common Name English
E3710
Code English
(R)-2-(((4-((2,2-DIMETHYL-1,3-DIOXAN-5-YL)METHOXY)-3,5-DIMETHYLPYRIDIN-2-YL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE SODIUM SALT
Common Name English
1H-BENZIMIDAZOLE, 2-((R)-((4-((2,2-DIMETHYL-1,3-DIOXAN-5-YL)METHOXY)-3,5-DIMETHYL-2-PYRIDINYL)METHYL)SULFINYL)-, SODIUM SALT (1:1)
Common Name English
E-3710
Code English
Code System Code Type Description
CAS
955095-47-3
Created by admin on Sat Dec 16 02:07:41 GMT 2023 , Edited by admin on Sat Dec 16 02:07:41 GMT 2023
PRIMARY
PUBCHEM
23680578
Created by admin on Sat Dec 16 02:07:41 GMT 2023 , Edited by admin on Sat Dec 16 02:07:41 GMT 2023
PRIMARY
FDA UNII
KDJ60607ON
Created by admin on Sat Dec 16 02:07:41 GMT 2023 , Edited by admin on Sat Dec 16 02:07:41 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY